Table 1.
Baseline demographics of the cohort and stratified by primary outcome measure
| Characteristics | Total cohort (N = 118) | With primary outcome (N = 20) | Without primary outcome (N = 98) | P-value |
|---|---|---|---|---|
| Age in years | 57 ± 14 | 61 ± 13 | 57 ± 14 | 0.23 |
| Female, n (%) | 50 (42) | 9 (45) | 41 (42) | 0.81 |
| BMI | 29 ± 6 | 30 ± 7 | 29 ± 6 | 0.90 |
| Hypertension, n (%) | 48 (41) | 11 (55) | 37 (38) | 0.21 |
| Diabetes, n (%) | 20 (17) | 6 (30) | 14 (14) | 0.11 |
| Hyperlipidemia, n (%) | 40 (34) | 8 (40) | 32 (33) | 0.61 |
| Smoking, n (%) | 39 (33) | 6 (30) | 33 (34) | 1.0 |
| QRS interval (ms) | 138 ± 31 | 144 ± 26 | 137 ± 32 | 0.32 |
| QTc (ms) | 469 ± 42 | 472 ± 37 | 469 ± 44 | 0.54 |
| Device implantation, n (%) | 56 (47) | 17 (85) | 39 (40) | <0.001* |
| NYHA functional class, n(%) | 0.05 | |||
| I | 12 (10) | 0(0) | 12(12) | |
| II | 51 (43) | 6 (30) | 45 (46) | |
| III | 46 (39) | 13 (65) | 33 (34) | |
| IV | 9 (8) | 1 (5) | 8 (8) | |
| Medicationsa | ||||
| ACE inhibitor or ARB | 86 (85) | 17 (94) | 69 (83) | 0.30 |
| Amiodarone | 5 (5) | 1 (6) | 4 (5) | 1.0 |
| Beta-blocker | 89 (88) | 17 (94) | 72 (87) | 0.69 |
| Calcium Blocker | 7 (7) | 2 (11) | 5(6) | 0.61 |
| Digoxin | 22 (22) | 5 (28) | 17 (20) | 0.53 |
| Diuretics | 70 (69) | 18 (100) | 52 (63) | <0.01* |
| Statin | 40 (40) | 6 (33) | 34 (41) | 0.61 |
Continuous data are expressed as mean ± SD, categorical data as n (%). *p < 0.05
Abbreviations: BMI Body mass index, NYHA New York Heart Association, ACE Angiotensin converting enzyme, ARB Angiotensin II receptor blocker. aTotal number of the patients for the medications data is 101